Nordea Investment Management AB Buys 232,690 Shares of Dynavax Technologies Co. (NASDAQ:DVAX)

Nordea Investment Management AB boosted its position in Dynavax Technologies Co. (NASDAQ:DVAX) by 42.7% during the 4th quarter, HoldingsChannel.com reports. The firm owned 777,816 shares of the biopharmaceutical company’s stock after purchasing an additional 232,690 shares during the quarter. Nordea Investment Management AB’s holdings in Dynavax Technologies were worth $10,034,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the company. GAMMA Investing LLC lifted its holdings in shares of Dynavax Technologies by 175.5% during the 3rd quarter. GAMMA Investing LLC now owns 2,645 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 1,685 shares during the last quarter. US Bancorp DE raised its holdings in shares of Dynavax Technologies by 291.4% during the 3rd quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 2,034 shares in the last quarter. Capital Performance Advisors LLP purchased a new stake in Dynavax Technologies in the third quarter worth approximately $45,000. Nisa Investment Advisors LLC grew its position in Dynavax Technologies by 44.6% during the third quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company’s stock valued at $61,000 after acquiring an additional 1,679 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB bought a new stake in shares of Dynavax Technologies in the 3rd quarter worth approximately $89,000. 96.96% of the stock is currently owned by hedge funds and other institutional investors.

Dynavax Technologies Stock Down 1.6 %

Shares of Dynavax Technologies stock opened at $12.62 on Friday. The company’s 50 day moving average price is $12.72 and its 200-day moving average price is $11.62. Dynavax Technologies Co. has a 52-week low of $9.74 and a 52-week high of $14.41. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23. The stock has a market capitalization of $1.66 billion, a price-to-earnings ratio of 97.08 and a beta of 1.34.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and set a $29.00 target price on shares of Dynavax Technologies in a report on Friday, November 8th.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.